Bellen Bags ￥100M in Series D Financing

According to VCBeat, in June 2020, Bellen Chemistry Co., Ltd. ("Bellen") completed its Series D round of hundreds of millions, led by Huagai Capital and Eastern Bell Capital. Previous backers including CICC Capital's sub-fund CICC Qichen, Legend Capital, Apricot Capital, and Insight Capital also participated in the latest round.

The fund raised will be used for the development of the Bellen's CRO and CDMO businesses and the service platform for the R&D and chemical synthesis of small molecule drugs.

Bellen, established in 2007, originally focused on the design and development of hundreds of novel heterocycles. Over a number of years, Bellen's innovative capabilities and reliable performance were gradually becoming more recognized in the marketplace and then the company began to develop CRO/CDMO business with its clients.

Bellen is committed to creating the world's leading one-stop service platform for small molecule drug R&D and synthesis.  After three rounds of venture capital financing, a manufacturing plant has been constructed in Shandong in addition to a new process R&D center in Shanghai since 2017. Bellen is planning for the relocation of its R&D innovation center to a new site in Beijing by the end of 2020.

Bellen's services cover candidate molecules R&D, production process development, industrialization, large-scale processing of commercial drugs, and others, forming a professional service platform. With strong innovative capability, perfect quality management and EHS management system, and more than ten years of experience in the field of drug R&D, Bellen continues to provide quality services for well-known pharmaceutical companies and drug R&D institutions in global and has established strategic partnerships with more and more customers.

Huagai Capital is a private equity investment firm that invests in start-up or growth companies in the areas of healthcare, TMT, and culture, with funds under management of 15 billion yuan. Its healthcare fund focuses on the fields of biomedicine, medical devices, and medical services.

Eastern Bell Capital, established in 2010, is an ecosystem-based fund engaged in include logistics, supply chain, retail & brand, data technology, etc. With AUM of 13 billion yuan, Eastern Bell Capital has invested 130 enterprises, 15 of which have grown into leaders in their industry.